PMN — ProMIS Neurosciences Share Price
Last trade - 00:00- $39.67m
- $37.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 371.35 | ||
| Price to Tang. Book | 371.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1437.77% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0 | 0 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
Directors
- Eugene Williams CHM
- Elliot Goldstein PRE (69)
- Neil Cashman CFD
- Daniel Geffken CFO (64)
- Johanne Kaplan OTH
- James Kupiec OTH (68)
- David Wishart OTH
- Josh Mandel-Brehm DRC
- Maggie Shafmaster DRC
- Richard Gregory IND (63)
- Patrick Kirwin IND
- Neil Warma IND
- William Wyman IND
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 21st, 2005
- Public Since
- April 3rd, 2017
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 18,961,116
- Address
- Suite 200, 1920 Yonge Street, TORONTO, M4S 3E2
- Web
- https://www.promisneurosciences.com/
- Phone
- +1 4168476898
- Auditors
- BAKER TILLY US LLP
Upcoming Events for PMN
Similar to PMN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 22:46 UTC, shares in ProMIS Neurosciences are trading at $1.51. This share price information is delayed by 15 minutes.
Shares in ProMIS Neurosciences last closed at $1.51 and the price had moved by -64.39% over the past 365 days. In terms of relative price strength the ProMIS Neurosciences share price has underperformed the S&P500 Index by -71.66% over the past year.
The overall consensus recommendation for ProMIS Neurosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
ProMIS Neurosciences does not currently pay a dividend.
ProMIS Neurosciences does not currently pay a dividend.
ProMIS Neurosciences does not currently pay a dividend.
To buy shares in ProMIS Neurosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.51, shares in ProMIS Neurosciences had a market capitalisation of $28.63m.
Here are the trading details for ProMIS Neurosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PMN
Based on an overall assessment of its quality, value and momentum ProMIS Neurosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ProMIS Neurosciences is $8.75. That is 479.17% above the last closing price of $1.51.
Analysts covering ProMIS Neurosciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.52 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ProMIS Neurosciences. Over the past six months, its share price has outperformed the S&P500 Index by +28.09%.
As of the last closing price of $1.51, shares in ProMIS Neurosciences were trading -16.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ProMIS Neurosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ProMIS Neurosciences' management team is headed by:
- Eugene Williams - CHM
- Elliot Goldstein - PRE
- Neil Cashman - CFD
- Daniel Geffken - CFO
- Johanne Kaplan - OTH
- James Kupiec - OTH
- David Wishart - OTH
- Josh Mandel-Brehm - DRC
- Maggie Shafmaster - DRC
- Richard Gregory - IND
- Patrick Kirwin - IND
- Neil Warma - IND
- William Wyman - IND